Literature DB >> 11467641

Impact of cessation of smoking on the course of ulcerative colitis.

L Beaugerie1, N Massot, F Carbonnel, S Cattan, J P Gendre, J Cosnes.   

Abstract

OBJECTIVES: The incidence and severity of ulcerative colitis (UC) are higher in nonsmokers than in smokers. The natural course of UC in smokers who stop smoking is not known. The aim of this study was to determine the impact of cessation of smoking on the course of UC among the cohort of patients regularly seen at our institution.
METHODS: The severity of UC, as judged by the occurrence of flare-ups and the need for systemic steroids, immunosuppressive drugs and colectomy, was determined in 32 patients with UC who stopped smoking after the diagnosis of UC. We compared the period after cessation of smoking (7-yr mean follow-up) with the period between the onset of the disease and the cessation of smoking (9-yr mean duration). The course of UC in this group was compared with that of 32 nonsmokers and 32 continuing smokers matched for sex, age, and age at onset.
RESULTS: In patients who quit, cessation of smoking was followed by an increase in the rate of years with active disease (p < 0.01), years with hospitalization (p < 0.05) and years with major medical therapy (oral steroids, intravenous steroids, and azathioprine, p < 0.01). After cessation of smoking, the rate of years with immunosuppressive therapy was significantly greater in ex-smokers and nonsmokers than in continuing smokers (p < 0.01). The risk of colectomy in ex-smokers after smoking cessation was similar to that of nonsmokers and continuing smokers.
CONCLUSIONS: In smokers with UC who stop smoking, the severity of the disease increases after smoking cessation, with an increase in the disease activity and the need for hospital admission and major medical therapy. In addition, the need for azathioprine therapy becomes similar to that of nonsmokers.

Entities:  

Mesh:

Year:  2001        PMID: 11467641     DOI: 10.1111/j.1572-0241.2001.03944.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

1.  Smoking and inflammatory bowel diseases: what in smoking alters the course?

Authors:  A M El-Tawil
Journal:  Int J Colorectal Dis       Date:  2010-03-24       Impact factor: 2.571

Review 2.  Smoking in inflammatory bowel diseases: good, bad or ugly?

Authors:  Peter Laszlo Lakatos; Tamas Szamosi; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 3.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

Review 4.  The intestinal microbiota: its role in health and disease.

Authors:  Luc Biedermann; Gerhard Rogler
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

Review 5.  Ulcerative colitis in smokers, non-smokers and ex-smokers.

Authors:  Guillermo Bastida; Belén Beltrán
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 6.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

7.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

8.  Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

Authors:  Harry Sokol; Jacques Cosnes; Olivier Chazouilleres; Laurent Beaugerie; Emmanuel Tiret; Raoul Poupon; Philippe Seksik
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 9.  Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.

Authors:  Alyssa Parian; Berkeley Limketkai; Joyce Koh; Steven R Brant; Alain Bitton; Judy H Cho; Richard H Duerr; Dermot P McGovern; Deborah D Proctor; Miguel D Regueiro; John D Rioux; Phil Schumm; Kent D Taylor; Mark S Silverberg; A Hillary Steinhart; Ruben Hernaez; Mark Lazarev
Journal:  Gut       Date:  2016-04-13       Impact factor: 23.059

10.  Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease.

Authors:  Marian C Aldhous; Colin L Noble; Jack Satsangi
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.